Lipoproteins, sex hormones and inflammatory markers in association with prostate cancer

References

• Fleshner N, Zlotta AR. Prostate cancer prevention: past, present, and future. Cancer 2007;110:1889–1899.
   PubMed Web of Science ®Google Scholar
• Fradet V, Cheng I, Casey G, Witte JS. Dietary omega-3 fatty acids, cyclooxygenase-2 genetic variation, and aggressive prostate cancer risk. Clin Cancer Res 2009;15:2559–2566.
   PubMed Web of Science ®Google Scholar
• Freedland SJ, Aronson WJ. Dietary intervention strategies to modulate prostate cancer risk and prognosis. Curr Opin Urol 2009;19:263–267.
   PubMed Web of Science ®Google Scholar
• Dal Maso L, Zucchetto A, La Vecchia C, Montella M, Conti E, Canzonieri V, Talamini R, Tavani A, Negri E, Garbeglio A, Franceschi S. Prostate cancer and body size at different ages: an Italian multicentre case-control study. Br J Cancer 2004;90:2176–2180.
   Google Scholar
• Lagiou A, Samoli E, Georgila C, Minaki P, Barbouni A, Tzonou A, Trichopoulos D, Lagiou P. Occupational physical activity in relation with prostate cancer and benign prostatic hyperplasia. Eur J Cancer Prev 2008;17:336–339.
   PubMed Web of Science ®Google Scholar
• Wiklund F, Lageros YT, Chang E, Bälter K, Johansson JE, Adami HO, Grönberg H. Lifetime total physical activity and prostate cancer risk: a population-based case-control study in Sweden. Eur J Epidemiol 2008;23:739–746.
   Google Scholar
• Moore SC, Peters TM, Ahn J, Park Y, Schatzkin A, Albanes D, Ballard-Barbash R, Hollenbeck A, Leitzmann MF. Physical activity in relation n to total, advanced, and fatal prostate cancer. Cancer Epidemiol Biomarkers Prev 2008;17:2458–2466.
   Google Scholar
• Freedland SJ, Giovannucci E, Platz EA. Are findings from studies of obesity and prostate cancer really in conflict? Cancer Causes Control 2006;17:5–9.
   PubMed Web of Science ®Google Scholar
• Pischon T, Boeing H, Weikert S, Allen N, Key T, Johnsen NF, Tjønneland A, Severinsen MT, Overvad K, Rohrmann S, et al Body size and risk of prostate cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 2008;17:3252–3261.
   PubMed Web of Science ®Google Scholar
• Suzuki S, Platz EA, Kawachi I, Willett WC, Giovannucci E. Intakes of energy and macronutrients and the risk of benign prostatic hyperplasia. Am J Clin Nutr 2002;75:689–697.
   PubMed Web of Science ®Google Scholar
• Parsons JK, Bergstrom J, Barrett-Connor E. Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community-dwelling men. BJU Int 2008;101:313–318.
   PubMed Web of Science ®Google Scholar
• Laukkanen JA, Laaksonen DE, Niskanen L, Pukkala E, Hakkarainen A, Salonen JT. Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study. Cancer Epidemiol Biomarkers Prev 2004;13:1646–1650.
   PubMed Web of Science ®Google Scholar
• Hsing AW, Gao YT, Chua S Jr, Denq J, Stanczyk FZ. Insulin resistance and prostate cancer risk. J Natl Cancer Inst 2003;95:67–71.
   PubMed Web of Science ®Google Scholar
• Sekine Y, Koike H, Nakano T, Nakajima K, Suzuki K. Remnant lipoproteins stimulate proliferation and activate MAPK and Akt signaling pathways via G protein-coupled receptor in PC-3 prostate cancer cells. Clin Chim Acta 2007;383:78–84.
   Google Scholar
• Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008;100:170–183.
   PubMed Web of Science ®Google Scholar
• Bernoulli J, Yatkin E, Laakso A, Anttinen M, Bosland M, Vega K, Kallajoki M, Santti R, Pylkkänen L. Histopathological evidence for an association of inflammation with ductal pin-like lesions but not with ductal adenocarcinoma in the prostate of the noble rat. Prostate 2008;15:728–739.
   Google Scholar
• Schatzl G, Madersbacher S, Thurridl T, Waldmüller J, Kramer G, Haitel A, Marberger M. High-grade prostate cancer is associated with low serum testosterone levels. Prostate 2001;47:52–58.
   PubMed Web of Science ®Google Scholar
• Baillargeon J, Rose DP. Obesity, adipokines, and prostate cancer (review). Int J Oncol 2006;28:737–745.
   PubMed Web of Science ®Google Scholar
• Il'yasova D, Colbert LH, Harris TB, Newman AB, Bauer DC, Satterfield S, Kritchevsky SB.Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev 2005;14:2413–2418.
   PubMed Web of Science ®Google Scholar
• Helzlsouer KJ, Erlinger TP, Platz EA. C-reactive protein levels and subsequent cancer outcomes: results from a prospective cohort study. Eur J Cancer 2006;42:704–707.
   PubMed Web of Science ®Google Scholar
• Goktas S, Yilmaz MI, Caglar K, Sonmez A, Kilic S, Bedir S. Prostate cancer and adiponectin. Urology 2005;65:1168–1172.
   PubMed Web of Science ®Google Scholar
• Housa D, Vernerová Z, Herácek J, Procházka B, Cechák P, Kuncová J, Haluzik M. Adiponectin as a potential marker of prostate cancer progression: studies in organ-confined and locally advanced prostate cancer. Physiol Res 2008;57:451–458.
   PubMed Web of Science ®Google Scholar
• McLaughlin T, Reaven G, Abbasi F, Lamendola C, Saad M, Waters D, Simon J, Krauss RM. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? Am J Cardiol 2005;96:399–404.
   PubMed Web of Science ®Google Scholar
• Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625–1638.
   PubMed Web of Science ®Google Scholar
• Engeland A, Tretli S, Bjorge T. Height, body mass index, and prostate cancer: a follow-up of 950000 Norwegian men. Br J Cancer 2003;89:1237–1242.
   PubMed Web of Science ®Google Scholar
• Michalakis K, Williams CJ, Mitsiades N, Blakeman J, Balafouta-Tselenis S, Giannopoulos A, Mantzoros CS Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: a case control study. Cancer Epidemiol Biomarkers Prev 2007;16:308–313.
   PubMed Web of Science ®Google Scholar
• Nandeesha H, Koner BC, Dorairajan LN. Altered insulin sensitivity, insulin secretion and lipid profile in non-diabetic prostate carcinoma. Acta Physiol Hung 2008;95:97–105.
   Google Scholar
• Hammarsten J, Hogstedt B. Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer. Eur J Cancer 2005;41:2887–2895.
   PubMed Web of Science ®Google Scholar
• Wuermli L, Joerger M, Henz S, et al Hypertriglyceridemia as a possible risk factor for prostate cancer. Prostate Cancer Prostatic Dis 2005;8:316–320.
   PubMed Web of Science ®Google Scholar
• Travis RC, Key TJ, Allen NE, et al Serum androgens and prostate cancer among 643 cases and 643 controls in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2007;121:1331–1338.
   PubMed Web of Science ®Google Scholar
• Wiren S, Stocks T, Rinaldi S, et al Androgens and prostate cancer risk: a prospective study. Prostate 2007;67:1230–1237.
   PubMedGoogle Scholar
• Ho SM. Estrogens and anti-estrogens: key mediators of prostate carcinogenesis and new therapeutic candidates. J Cell Biochem 2004;91:491–503.
   PubMed Web of Science ®Google Scholar
• Pearson TA, Mensah GA, Alexander RW. Markers of inflammation and cardiovascular disease. Circulation 2003;107:499–511.
   PubMed Web of Science ®Google Scholar
• McArdle PA, Mir K, Almushatat AS, Wallace AM, Underwood MA, McMillan DC. Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer. Urol Int 2006;77:127–129.
   Google Scholar
• Lehrer S, Diamond EJ, Mamkine B, Droller MJ, Stone NN, Stock RG. C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer. BJU Int 2005;95:961–962.
   PubMed Web of Science ®Google Scholar
• Siemes C, Visser LE, Coebergh JW, et al C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J Clin Oncol 2006;24:5216–5222.
   PubMed Web of Science ®Google Scholar
• Sher DJ, Oh WK, Jacobus S, Regan MM, Lee GS, Mantzoros C. Relationship between serum adiponectin and prostate cancer grade. Prostate 2008;68:1592–1598.
   PubMed Web of Science ®Google Scholar
• Coffey DS, Walsh PC. Clinical and experimental studies of benign prostatic hyperplasia. Urol Clin North Am 1990;17:461–475.
   PubMed Web of Science ®Google Scholar
• Parsons JK, Carter HB, Partin AW, et al Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab 2006;91:2562–2568.
   PubMed Web of Science ®Google Scholar